Page 1695 - Hematology_ Basic Principles and Practice ( PDFDrive )

Chapter 93 Late Complications of Hematologic Diseases and Their Therapies 1512.e1

REFERENCES 24. Armenian SH, Sun CL, Shannon T, et al: Incidence and predictors of
congestive heart failure after autologous hematopoietic cell transplanta-
1. Siegel R, Naishadham D, Jemal A: Cancer statistics, 2013. CA Cancer tion. Blood 118(23):6023–6029, 2011.
J Clin 63(1):11–30, 2013. 25. Tichelli A, Bucher C, Rovo A, et al: Premature cardiovascular disease
2. American Cancer Society: Cancer treatment and survivorship facts and after allogeneic hematopoietic stem-cell transplantation. Blood
figures 2014-2015, Atlanta, 2014, American Cancer Society. 110(9):3463–3471, 2007.
3. Armenian SH, Meadows AT, Bhatia S: Late effects of childhood 26. Tichelli A, Passweg J, Wojcik D, et al: Late cardiovascular events after
cancer and its treatment. In Pizzo PA, Poplack DG, editors: Principles allogeneic hematopoietic stem cell transplantation: a retrospective
and practice of pediatric oncology, Philadelphia, 2011, Lippincott Raven, multicenter study of the Late Effects Working Party of the Euro-
pp 1431–1462. pean Group for Blood and Marrow Transplantation. Haematologica
4. Hudson MM: Late complications after leukemia therapy. In Pui CH, 93(8):1203–1210, 2008.
editor: Childhood leukemias, Cambridge, 2006, Cambridge University 27. Armstrong GT, Liu Q, Yasui Y, et al: Late mortality among 5-year
Press. survivors of childhood cancer: a summary from the Childhood Cancer
5. Bhatia S, Landier W, Robison LL: Late effects of childhood cancer Survivor Study. J Clin Oncol 27(14):2328–2338, 2009.
therapy. In DeVita VT, Hellman S, Rosenberg SA, editors: Progress in 28. Mulrooney DA, Yeazel MW, Kawashima T, et al: Cardiac outcomes
oncology, Sudbury, MA, 2002, Jones and Bartlett, pp 171–213. in a cohort of adult survivors of childhood and adolescent cancer:
6. Oeffinger KC, Mertens AC, Sklar CA, et al: Chronic health conditions in retrospective analysis of the Childhood Cancer Survivor Study cohort.
adult survivors of childhood cancer. N Engl J Med 355(15):1572–1582, BMJ 339:b4606, 2009.
2006. 29. van Dalen EC, van der Pal HJ, Kok WE, et al: Clinical heart failure in
7. Tarleton HP, Ryan-Ibarra S, Induni M: Chronic disease burden among a cohort of children treated with anthracyclines: a long-term follow-up
cancer survivors in the California Behavioral Risk Factor Surveillance study. Eur J Cancer 42(18):3191–3198, 2006.
System, 2009-2010. J Cancer Surviv 8(3):448–459, 2014. 30. Pein F, Sakiroglu O, Dahan M, et al: Cardiac abnormalities 15 years
8. Landier W, Armenian S, Bhatia S: Late effects of childhood cancer and and more after adriamycin therapy in 229 childhood survivors of a
its treatment. Pediatr Clin North Am 62(1):275–300, 2015. solid tumour at the Institut Gustave Roussy. Br J Cancer 91(1):37–44,
9. Zafar SY, McNeil RB, Thomas CM, et al: Population-based assessment 2004.
of cancer survivors’ financial burden and quality of life: a prospective 31. Blanco JG, Sun CL, Landier W, et al: Anthracycline-related cardio-
cohort study. J Oncol Pract 11(2):145–150, 2015. myopathy after childhood cancer: role of polymorphisms in carbonyl
10. Hudson MM, Oeffinger KC, Jones K, et al: Age-dependent changes in reductase genes–a report from the Children’s Oncology Group. J Clin
health status in the Childhood Cancer Survivor cohort. J Clin Oncol Oncol 30(13):1415–1421, 2012.
33(5):479–491, 2015. 32. Swain SM, Whaley FS, Ewer MS: Congestive heart failure in patients
11. Guy GP, Jr, Ekwueme DU, Yabroff KR, et al: Economic burden of treated with doxorubicin: a retrospective analysis of three trials. Cancer
cancer survivorship among adults in the United States. J Clin Oncol 97(11):2869–2879, 2003.
31(30):3749–3757, 2013. 33. Aleman BM, van den Belt-Dusebout AW, De Bruin ML, et al:
12. Phillips SM, Padgett LS, Leisenring WM, et al: Survivors of childhood Late cardiotoxicity after treatment for Hodgkin lymphoma. Blood
cancer in the United States: prevalence and burden of morbidity. Cancer 109(5):1878–1886, 2007.
Epidemiol Biomarkers Prev 24(4):653–663, 2015. 34. Myrehaug S, Pintilie M, Tsang R, et al: Cardiac morbidity follow-
13. Socie G, Salooja N, Cohen A, et al: Nonmalignant late effects after ing modern treatment for Hodgkin lymphoma: supra-additive
allogeneic stem cell transplantation. Blood 101(9):3373–3385, 2003. cardiotoxicity of doxorubicin and radiation therapy. Leuk Lymphoma
14. Leiper AD: Non-endocrine late complications of bone marrow trans- 49(8):1486–1493, 2008.
plantation in childhood: part I. Br J Haematol 118(1):3–22, 2002. 35. Drafts BC, Twomley KM, D’Agostino R, Jr, et al: Low to moderate dose
15. Leiper AD: Non-endocrine late complications of bone marrow anthracycline-based chemotherapy is associated with early noninvasive
transplantation in childhood: part II. Br J Haematol 118(1):23–43, imaging evidence of subclinical cardiovascular disease. JACC Cardiovasc
2002. Imaging 6(8):877–885, 2013.
16. Brennan BM, Shalet SM: Endocrine late effects after bone marrow 36. Limat S, Daguindau E, Cahn JY, et al: Incidence and risk-factors
transplant. Br J Haematol 118(1):58–66, 2002. of CHOP/R-CHOP-related cardiotoxicity in patients with aggres-
17. Baker KS, Gurney JG, Ness KK, et al: Late effects in survivors of sive non-Hodgkin’s lymphoma. J Clin Pharm Ther 39(2):168–174,
chronic myeloid leukemia treated with hematopoietic cell transplanta- 2014.
tion: results from the Bone Marrow Transplant Survivor Study. Blood 37. Hershman DL, McBride RB, Eisenberger A, et al: Doxorubicin, cardiac
104(6):1898–1906, 2004. risk factors, and cardiac toxicity in elderly patients with diffuse B-cell
18. Fraser CJ, Bhatia S, Ness K, et al: Impact of chronic graft-versus- non-Hodgkin’s lymphoma. J Clin Oncol 26(19):3159–3165, 2008.
host disease on the health status of hematopoietic cell transplantation 38. Herbrecht R, Cernohous P, Engert A, et al: Comparison of
survivors: a report from the Bone Marrow Transplant Survivor Study. pixantrone-based regimen (CPOP-R) with doxorubicin-based therapy
Blood 108(8):2867–2873, 2006. (CHOP-R) for treatment of diffuse large B-cell lymphoma. Ann Oncol
19. Sun CL, Francisco L, Kawashima T, et al: Prevalence and predictors 24(10):2618–2623, 2013.
of chronic health conditions after hematopoietic cell transplantation: 39. Armenian SH, Sun CL, Francisco L, et al: Late congestive heart failure
a report from the Bone Marrow Transplant Survivor Study. Blood after hematopoietic cell transplantation. J Clin Oncol 26(34):5537–
116(17):3129–3139, quiz 3377, 2010. 5543, 2008.
20. Pundole XN, Barbo AG, Lin H, et al: Increased incidence of fractures 40. Murbraech K, Smeland KB, Holte H, et al: Heart Failure and Asymp-
in recipients of hematopoietic stem-cell transplantation. J Clin Oncol tomatic Left Ventricular Systolic Dysfunction in Lymphoma Survivors
33(12):1364–1370, 2015. Treated With Autologous Stem-Cell Transplantation: A National Cross-
21. Bhatia S: Caring for the long-term survivor after allogeneic stem Sectional Study. J Clin Oncol 33(24):2683–2891, 2015.
cell transplantation. Hematology Am Soc Hematol Educ Program 41. Godoy LY, Fukushige J, Igarashi H, et al: Anthracycline-induced
2014(1):495–503, 2014. cardiotoxicity in children with malignancies. Acta Paediatr Jpn
22. Sun CL, Kersey JH, Francisco L, et al: Burden of morbidity in 10+ year 39(2):188–193, 1997.
survivors of hematopoietic cell transplantation: report from the bone 42. Kremer LC, van Dalen EC, Offringa M, et al: Frequency and risk
marrow transplantation survivor study. Biol Blood Marrow Transplant factors of anthracycline-induced clinical heart failure in children: a
19(7):1073–1080, 2013. systematic review. Ann Oncol 13(4):503–512, 2002.
23. Chow EJ, Mueller BA, Baker KS, et al: Cardiovascular hospitalizations 43. Armenian SH, Bhatia S: Cardiovascular disease after hematopoietic
and mortality among recipients of hematopoietic stem cell transplanta- cell transplantation–lessons learned. Haematologica 93(8):1132–1136,
tion. Ann Intern Med 155(1):21–32, 2011. 2008.